Cooperative Agreement R43CA210839

This $167,000 federal Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) supports research at Cedars-Sinai Medical Center to develop a novel combinatorial immunotherapeutic strategy for treating metastatic uveal melanoma. The research aims to first use a tumor debulking approach with the drug combination of trametinib and panobinostat to reduce tumor load, and then apply B7-H3 chimeric antigen receptor (CAR) T-cell therapy to...

The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $799,107 Project Grant to the Dana-Farber Cancer Institute, Inc. in Boston, MA to conduct research on using genomic biomarkers and decision analysis frameworks to guide treatment decisions for stage III melanoma patients. The grant will fund a collaborative project involving researchers from Dana-Farber and Brigham & Women's Hospital to develop methods for translating genomic and...

This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $217,863 to the University of Colorado-Denver to compare natural killer (NK) cell profiles within melanoma tumors and during pregnancy. The objectives are to: 1) identify biomarkers that can predict risk of disease progression and response to immune checkpoint blockade (ICB) therapy for melanoma patients, and 2) define new therapeutic targets to limit disease progression or improve...

This Project Grant award from the National Cancer Institute under CFDA 93.395 - Cancer Treatment Research supports research to advance the understanding of how a novel neoadjuvant therapy using an anti-Semaphorin 4D (anti-Sema4D) antibody in combination with immune checkpoint blockade (ICB) impacts the immune system in patients with refractory melanoma. The $1,419,108 award to Emory University will enable the research team to gain insights into how blocking Sema4D signaling enhances the...

This federal Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), aims to improve mucosal melanoma therapy by harnessing the immunogenicity of the R3LCMV virus. The $667,553 award to Northwestern University, spanning 2025-2029, has two key objectives: Determine whether neoadjuvant R3LCMV treatment improves disease-free survival in dogs with naturally occurring mucosal melanoma through a placebo-controlled veterinary...

This Project Grant award for $679,604.00 was provided by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) to The Children's Hospital Corporation (Boston Children's Hospital) to evaluate pathways involved in the initiation and formation of melanoma using a zebrafish model. The research aims to reveal critical pathways that participate in melanoma development and progression, with the goal of advancing scientific knowledge to improve prevention, diagnosis,...

This $399,669 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for glioblastoma (GBM), the most common and deadly primary brain tumor. The key products or services to be delivered under this grant include: Evaluating the ability of the applicant's Prussian blue nanoparticle-based photothermal therapy (PBNP-PTT) platform to...

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Phase I Small Business Innovation Research (SBIR) grant for $305,000 awarded to Redpoint Oncology, Inc. aims to develop and validate a novel platform for targeted cancer therapies. The project seeks to create new cancer treatments designed to target and destroy cancer cells for a broad range of different cancers. The project's broader impact includes addressing critical unmet medical needs and...

This Cooperative Agreement award from the National Cancer Institute, a division of the Department of Health and Human Services, provides $380,509 under the Cancer Biology Research program to The Trustees of Columbia University in New York. The award supports research to elucidate the molecular drivers of melanoma liver metastasis and associated resistance to immunotherapies. Specifically, the researchers will characterize a novel preclinical mouse model that recapitulates genomic and...

This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $487,468 to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to conduct research on the role of protein palmitoylation in the progression of melanoma lung metastasis. The key objectives of the research project are to: Investigate how the palmitoyl transferase ZDHHC13 suppresses melanoma metastasis by stabilizing E-cadherin through palmitoylation...